SUE ROH: Open Payments
NPI 1619360310 · LEANDER, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,588 in 129 payments from 15 companies in 2025. Trend: 2023 $2,024 · 2024 $1,858 · 2025 $2,588
Food & beverage: $2,469Education: $119
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $384 |
| Otsuka America Pharmaceutical, Inc. | 20 | $329 |
| ABBVIE INC. | 21 | $298 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $285 |
| Alkermes, Inc. | 13 | $251 |
| E.R. Squibb & Sons, L.L.C. | 10 | $236 |
| Supernus Pharmaceuticals, Inc. | 16 | $199 |
| Vanda Pharmaceuticals Inc. | 9 | $155 |
| Axsome Therapeutics, Inc. | 6 | $137 |
| Neurocrine BioSciences, Inc. | 4 | $133 |
Products named: REXULTI, VRAYLAR, CAPLYTA, COBENFY, UZEDY, Qelbree, ARISTADA, FANAPT.
Industry payments across TX — which companies pay providers there.
